Travera

Did you know there's a way to test live cancer cells from a patient with different FDA-approved drugs to find the most effective treatment? This is what functional precision medicine is all about—delivering quick, personalized insights to help choose the best treatment for each unique cancer.

Curious to learn more? We’re exploring the evolution of this field, how it’s changing cancer care today, and the challenges of implementing these tests.

Our Ask the Expert session with Travera will be online at Smart Patients from September 9 to 11. To join the conversation, just sign up or sign in.

Follow this link to discover how functional precision medicine could change the future of cancer treatment:
https://ow.ly/L38T50T6Rkm

A standing ovation for Ovations ForThe Cure.

We applaud your unwavering commitment to providing support and relief to patients.

The knowledge, hope, comfort, and support you offer align perfectly with our mission at the Smart Patients online community - a space where patients can share experiences, find emotional support, and connect with others who truly understand their journey.

Join today:

https://ow.ly/GGnY50SReOn

Fighting Ovarian Cancer? Curious if you qualify for our FREE Early Access testing? Complete this form and if you qualify, Travera will work with you and your doctor to participate in this FREE program. See if you qualify here.
https://form.jotform.com/241784594580165?fbclid=IwY2xjawEghfJleHRuA2FlbQIxMQABHUCGyFXB_l3hO_fLQvUIL11gw9aFqk39b68TEURxNMP7plNEQR8MW5xGrA_aem_yTWl7OtzObOKA99qvqExxA

Check out the recorded webinar here: https://youtu.be/BIgJIu-qjj4?feature=shared&t=390

Travera is dedicated to expanding our efforts in ovarian cancer. We have efforts on-going to establish new clinical trial opportunities, but if you are fighting this disease today, you may qualify for our FREE Early Access Program. See if you qualify and learn more today.

Health Evaluation Form Please click the link to complete this form.

Travera was honored and humbled for the opportunity to participate in the June session of ACPMP - Appendix Cancer / Pseudomyxoma Peritonei Research Foundation 2024 Education Series, hosted by Deborah Shelton. It was a great venue to share more about Travera's technology, data, and future research goals in Appendix Cancer and other GI based malignancies. It was an engaged and knowledgeable group of scientist, patients, and care givers that asked great questions. We are so thankful for the invitation to participate and look forward to continuing our efforts in finding solutions for challenging diseases like Appendix Cancer.

Rob and Dennis were humbled to represent Travera at ASCO 2024. Great meetings, great science, friends, food, and progress! Thanks to all who connected with us, collaborators new and old. We look forward to many fruitful opportunities coming out of this time in Chicago!

We are excited for the opportunity to present on the exciting work Travera is doing in GI based malignancies, like appendiceal cancer with the Appendix Cancer Pseudomyxoma Peritonei (ACPMP) Research Foundation. Join us to learn more about the value we hope to bring to this space.

Exploring New Technology To Personalize Therapy Beyond Standard Approaches Optimizing Treatment Selection: Exploring A New Technology To Personalize Therapy Beyond Any Standard Approach

At Travera we are enthusiastic about the focused research we have in ovarian cancer and with frequency and mortality estimated to increase, we are hopeful that our technology can make an impact. If you are an ovarian cancer patient or advocate reach out to learn how we can partner in this endeavor. Ovarian Cancer Research Alliance OCRA Below The Belt Women's Cancer Outreach Teal Diva

Ovarian Cancer Key Stats* According to Globocan's 2022 projections, by 2050, the number of women around the world diagnosed with ovarian cancer will rise over 55% to 503,448. The number of women dying from ovarian cancer each year is projected to increase to 350,956 an increase of almost 70% from 2022. Five-year ovarian c

Congratulations to Ovarian Cancer Research Alliance OCRA on this amazing achievement.

Funding update! Congress passed a package of appropriations bills at the end of March that will fund the government for the remainder of the 2024 Fiscal Year, which includes $72.5 million for three ovarian cancer programs dedicated to research and education (Ovarian Cancer Research Program, Johanna’s Law and the Ovarian Cancer Control Initiative). This amount represents a $500,000 increase from the previous funding levels, with the Ovarian Cancer Control Initiative being the only cancer program at the Centers for Disease Control and Prevention (CDC) to get an increase. Thank you to all who answered our calls to action and urged your legislators to support this crucial funding. There’s still time to lend your voice to our Fiscal Year 2025 asks with a short message to Congress at https://www.votervoice.net/OCRA/Campaigns/113324/Respond.

A significant portion of women diagnosed with ovarian cancer will be deemed "platinum resistant". If you're one of those women, your viable treatment options become more limited and less efficacious. Travera's developing technology may help in informing personalized treatment decisions for women in these difficult situations. Learn more about our FREE EARLY ACCESS PROGRAM HERE! www.travera.com/ovarian-cancer

@

TRAVERA - Late-Stage Ovarian Cancer Navigating Late-Stage Ovarian Cancer For Late-Stage Patients and their Oncologists looking for effective Treatments Now Ovarian cancer is a particularly challenging disease that often goes undetected until it reaches an advanced stage. For those grappling with late-stage ovarian cancer, standard tre...